JeffreyAMeyerhardtMDMPH

Oncology • Boston, MA

Gastrointestinal Cancer, Hematologic Oncology

Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Meyerhardt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Meyerhardt's full profile

Already have an account?

Office
450 Brookline Ave
Dana-Farber Cancer Inst
Boston, MA 02215
Phone+1 617-632-6855

Fax+1 617-632-5370

Summary

Dr. Jeffrey Meyerhardt is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital. He received his medical degree from Yale University School of Medicine and has been in practice 20 years. He specializes in gastrointestinal oncology.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2002
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1997 - 2000
Yale School of MedicineClass of 1997

Certifications & Licensure

MA State Medical License 1999 - 2026
NH State Medical License 2024 - 2024
RI State Medical License 2020 - 2020
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer Start of enrollment: 2005 Jan 01
Completed
Phase 2
Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer Start of enrollment: 2002 Jul 01
Completed
Phase 2
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer Start of enrollment: 2003 Mar 01
Completed
Phase 2
ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer Start of enrollment: 2007 Feb 01
Completed
Phase 1
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer Start of enrollment: 2008 May 01
Terminated
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Exercise and Metformin in Colorectal and Breast Cancer Survivors Start of enrollment: 2011 May 01
Completed
Phase 2
FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study Start of enrollment: 2018 Feb 23
Completed
Not Applicable
Physical Activity In Gastrointestinal Cancer Start of enrollment: 2017 Dec 01
Completed
Not Applicable
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
ACTIVE_NOT_RECRUITING
PHASE3
Nivolumab+Ipilimumab+RT in MSS mCRC Start of enrollment: 2020 Oct 05
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Timely Reporting of Patient-Reported Outcomes in Cancer Clinical Trials: An Ethical Imperative.
Eric C Blackstone, Fabio Efficace, Jeffrey A Meyerhardt, Gregory A Abel
Journal of Clinical Oncology. 2025-04-01
Utilizing Patient Input in Rectal Cancer Trial Design.
Janet Alvarez, Wini Zambare, Manju George, Reese Garcia, Phuong Gallagher
Journal of the National Cancer Institute. 2025-03-19
Novel metabolomic predictors of incident colorectal cancer in men and women.
Jonathan M Downie, Amit D Joshi, Connor M Geraghty, Brendan J Guercio, Oana A Zeleznik
Journal of the National Cancer Institute. 2025-03-01

Journal Articles

Aspirin Use and Risk of Colorectal Cancer Among Older Adults
Long H Nguyen, Kimmie Ng, Jeffrey A Meyerhardt, Andrew T Chan, JAMA Oncology
Association of Diet Quality with Survival Among People with Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial
Kimmie Ng, Chloe Atreya, Howard S Hochster, James N Atkins, Richard M Goldberg, Charles D Blanke, Jeffrey A Meyerhardt, JAMA Network Open
Association of Coffee Intake with Survival in Patients with Advanced or Metastatic Colorectal Cancer
I-Wen Chang, Charles D Blanke, Alan P Venook, Richard M Goldberg, Jeffrey A Meyerhardt, Kimmie Ng, JAMA Oncology

Lectures

Lessons From IDEA: Duration in Stage II and III Colon Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Other

The roles of diet, physical activity, and body weight in cancer survivorship
Meyerhardt JA, Ligibel J
http://www.uptodate.com/contents/the-roles-of-diet-physical-activity-and-body-weight-in-cancer-survi
UpToDate, Wolters Kluwer Health - 2013-04-09
Cancer of the appendix and pseudomyxoma peritonei
Meyerhardt JA, Swanson R
http://www.uptodate.com/contents/cancer-of-the-appendix-and-pseudomyxoma-peritonei
UpToDate, Wolters Kluwer Health - 2013-03-22
Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy
Meyerhardt JA, LaCasce AS, Burstein H, Castells MC
http://www.uptodate.com/contents/infusion-reactions-to-therapeutic-monoclonal-antibodies-used-for-ca
UpToDate, Wolters Kluwer Health - 2013-03-22

Authored Content

Vitamin D Status After Colorectal Cancer Diagnosis and Patient Survival According to Immune Response to TumourOctober 2018

Press Mentions

Exercise Helps Colon Cancer Survivors Live LongerMarch 28th, 2025
Celecoxib Lowers Colon Cancer Recurrence RiskJanuary 29th, 2025
Blood Test Identifies Advanced Colon Cancer Patients Who Benefit from CelecoxibJanuary 29th, 2025
Join now to see all

Grant Support

Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon CancerLSU PENNINGTON BIOMEDICAL RESEARCH CTR2022–2027
Exercise And Metformin To Impact Hyperinsulinemia In Colorectal Cancer SurvivorsNational Cancer Institute2011
The Influence Of Diet And Lifestyle On Patients With Advanced Colorectal CancerNational Cancer Institute2010–2011
The Role Of Pi3-Kinase Signaling Pathway In Defining Sensitivity And ResistanceNational Cancer Institute2007–2011
Predictors Of Outcome In Colorectal CancerNational Cancer Institute2003–2007